Article type
Abstract
Background: Bronchiectasis occurred in a 89-year-old man with chronic obstructive pulmonary disease. The inhaled aminoglycoside antibiotic (80mg gentamicin in 2ml normal saline 3 times a day for 5 days) was administered via a tracheostomy tube because of renal insufficiency during hospitalisation.
Objectives: Gentamicin was generally used as intramuscular or intravenous injection. We aimed to confirm the efficacy of inhaled gentamicin based on an evidence approach.
Methods: Setting, patient, intervention, comparison and outcome were established (PICO, Table 1) to form a therapy question. In the Pubmed, Cochrane and other databases, using MeSH terms and Boolean logic combinations (Bronchiectasis AND (Inhaled OR Aerosolized OR Nebulized) Gentamicin) for the literature search. Filters were activated to randomised-controlled trials, published in the last 10 years, in humans. Finally the literature (Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9.) was selected for appraisal using the Critical Appraisal Skills Programme (CASP) checklist.
Results: Baseline characteristics of the experimental group were similar to the control group (P>0.05). Losses to follow-up were less than 20% in the study. Although the design was a single-masked study, indicators such as the primary microbiological endpoint were not influenced by subjective consciousness. Gentamicin inhalation for bronchiectasis reduced inflammation markers (P
Objectives: Gentamicin was generally used as intramuscular or intravenous injection. We aimed to confirm the efficacy of inhaled gentamicin based on an evidence approach.
Methods: Setting, patient, intervention, comparison and outcome were established (PICO, Table 1) to form a therapy question. In the Pubmed, Cochrane and other databases, using MeSH terms and Boolean logic combinations (Bronchiectasis AND (Inhaled OR Aerosolized OR Nebulized) Gentamicin) for the literature search. Filters were activated to randomised-controlled trials, published in the last 10 years, in humans. Finally the literature (Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9.) was selected for appraisal using the Critical Appraisal Skills Programme (CASP) checklist.
Results: Baseline characteristics of the experimental group were similar to the control group (P>0.05). Losses to follow-up were less than 20% in the study. Although the design was a single-masked study, indicators such as the primary microbiological endpoint were not influenced by subjective consciousness. Gentamicin inhalation for bronchiectasis reduced inflammation markers (P